MedAdvisor Limited (AU:MDR) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
MedAdvisor Limited anticipates a notable shift in revenue from the first half to the second half of FY25 due to lower-than-expected flu vaccination rates in the US. While the company’s Australian operations remain stable, MedAdvisor is counting on a diverse and strong second-half pipeline in the US to boost revenue. The company remains optimistic about a record-breaking second half, attributing this to strategic diversification efforts.
For further insights into AU:MDR stock, check out TipRanks’ Stock Analysis page.